Immix Biopharma, Inc (Nasdaq: IMMX) has shared positive updates on its ongoing Phase 1b/2a NEXICART-1 study, focusing on NXC-201, a novel BCMA-targeted CAR-T cell therapy for AL amyloidosis patients. 

According to the company, the latest clinical data reveals that the therapy is well-tolerated and holds potential efficacy in treating advanced cases of relapsed/refractory AL amyloidosis.

On Friday, $IMMX closed at $1.64, experiencing a decrease of $0.27 (14.14%).

In other news, WeTrade Group Inc. (Nasdaq: WETG) recently received a notification from NASDAQ regarding its failure to file the quarterly report on Form 10-Q for the quarter ended March 31, 2023, within the prescribed timeline. Consequently, the company is deemed non-compliant with Nasdaq's filing requirements under Listing Rule 5250(c)(1). This notification adds to the basis for potential delisting of WeTrade Group's securities from The Nasdaq Stock Market.

To rectify the situation, WeTrade Group said that it is actively preparing a plan to regain compliance and intends to submit the necessary materials to the Panel as soon as possible.

On Friday, $WETG closed at $0.042, reflecting a decrease of $0.009 (18.58%).

THIS IS NOT A RECOMMENDATION TO BUY OR SELL ANY SECURITY OR DIGITAL ASSET. Please consult with a professional investment advisor before purchasing or selling any securities viewed on or mentioned herein. (Read Full Disclaimer)